News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Gulf Resources, Inc. has filed a notification of late filing (Form NT 10-Q) for its quarterly report for the period ended June 30, 2026. The company requires additional time to finalize its financial statements and footnote disclosures. It anticipates filing the Form 10-Q within …
Singularity Future Technology Ltd. (SGLY) has announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1. The company had previously fallen below this threshold and was granted two compliance periods, with the deficiency matter now …
This article reports that Cingulate Inc. filed a Form 8K on August 13. The filing is brief and does not provide specific details about the content of the Form 8K. It notes that the information
Cingulate Inc. reported its Q2 2026 financial results, showing no product revenue and a net loss of $5.87 million, an increase from $4.98 million in the prior-year quarter. Key business developments include receiving an FDA complete response letter for CTx-1301 requesting additional CMC data, …
Cingulate Inc. reported a net loss of $5.9 million for the second quarter of 2026, with cash and cash equivalents totaling $28.4 million. The company is preparing for a resubmission of its CTx-1301 ADHD treatment NDA following an FDA Complete Response Letter. Cingulate anticipates …
Cingulate reported its second-quarter 2026 financial results, showing $28.4 million in cash and cash equivalents and a net loss of $5.9 million. The company expects its cash runway to extend into mid-2027 as it progresses with NDA resubmission work for CTx-1301 and builds commercial …
Cingulate Inc. (NASDAQ:CING) reported a net loss of $5.9 million for Q2 2026 and announced plans to resubmit its New Drug Application for CTx-1301, an ADHD treatment, after receiving a Complete Response Letter from the FDA requesting additional chemistry, manufacturing, and controls information. The …
Cingulate Inc. reported its second-quarter 2026 financial results, highlighting $28.4 million in cash and cash equivalents, expected to fund operations into mid-2027. The company is advancing its CTx-1301 ADHD drug toward NDA resubmission following an FDA Complete Response Letter and secured a new U.S. …
5 Insightful Analyst Questions From Gulfport Energy's Q2 Earnings Call Gulfport Energy's second quarter was marked by a steep year-on-year revenue decline and a significant drop in oil production, which contributed to a negative market reaction. Management attributed the underperformance to lower commodity prices …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Gulfport Energy stock has delivered a strong 158.4% total return over the past 5 years, yet its current valuation checks still suggest the shares lean …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Earnings, production trends and leadership changes come together Gulfport Energy (GPOR) is back in focus after second quarter 2026 earnings showed revenue of US$323.23 …
Cingulate Inc. (NASDAQ: CING) announced the publication of peer-reviewed data in CNS Drugs detailing the pharmacokinetic profile of its lead ADHD product candidate, CTx-1301. The study demonstrated that CTx-1301 provides rapid initial dexmethylphenidate exposure comparable to existing treatments, but crucially maintains statistically higher plasma …
Cingulate (CING) is projected to report its Q2 2026 earnings before market open on Tuesday, August 18th, with analysts forecasting a loss of $0.63 per share and revenue of $167,000. The company previously missed Q1 2026 consensus estimates with a loss of $0.95 per …
Cingulate Inc. announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in CNS Drugs, showcasing the differentiated pharmacokinetic profile of its lead ADHD product candidate, CTx-1301. The study supports Cingulate’s Precision Timed Release™ (PTR™) platform, demonstrating rapid onset and extended medication …
In early August 2026, Gulfport Energy reported second-quarter revenue of US$323.23 million and net income of US$87.1 million, issued full-year 2026 production guidance, detailed further share repurchases, and announced the upcoming resignation of its Chief Financial Officer, Michael Hodges. The contrast between weaker quarterly …
Search by ticker symbol or company name and select a result to open its chart.